PMID- 36628339 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230112 IS - 1178-6965 (Print) IS - 1178-6965 (Electronic) IS - 1178-6965 (Linking) VI - 16 DP - 2023 TI - Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study. PG - 9-21 LID - 10.2147/JAA.S375325 [doi] AB - PURPOSE: Data on severe non-eosinophilic asthma are scarce. Moreover, as compared with eosinophilic asthma, non-eosinophilic asthma less frequently benefits from the latest therapeutic advances. This study aimed to highlight differences between non-eosinophilic and eosinophilic asthma as they may help the development of new therapeutic agents. PATIENTS AND METHODS: Data from 1075 adult patients with severe asthma (GINA treatment: 4/5) collected during the cross-sectional non-interventional FASE-CPHG study were analyzed. Two groups of patients (EOS-/EOS+) were constituted based on blood eosinophil counts (cutoff value: 300 G/l). Characteristics of EOS- (N = 500) and EOS+ (N = 575) patients were described; EOS- patients were also described according to their allergic profile based on skin allergy or allergen-specific immunoglobulin E (IgE) assays (cutoff value: 150 IU/mL). RESULTS: Percentages of patients with obesity (29%), allergen sensitization (57%), or >/=2 annual exacerbations in the last 12 months (68%) were similar in both groups. As compared with EOS+ patients, EOS- patients less frequently reported chronic rhinitis (41.1% vs 50.5%, p < 0.01) or nasal polyposis (13.6% vs 27.5%, p < 0.01), and more frequently reported GERD (45.2% vs 37.1%, p < 0.01), anxiety (45.5% vs 38.1%, p = 0.01), or depression (18.3% vs 13.3%, p = 0.02). EOS- patients had lower serum total IgE levels (median: 158 vs 319 IU/mL, p < 0.01) and were less frequently treated with long-term oral corticosteroid therapy (16.0% vs 23.7%; p < 0.01). Their asthma was more frequently uncontrolled (48% vs 40%, p < 0.01). Similar results were found with a cutoff value for blood eosinophil counts at 150 G/l. EOS- patients with allergic profile less frequently reported high serum IgE levels (35.6% vs 57.9%, p < 0.01). EOS- and EOS+ patients treated with long-term oral corticosteroids had similar profiles. CONCLUSION: In our patients with severe asthma, EOS- asthma was approximately as frequent as EOS+ asthma; EOS- asthma was frequently poorly controlled or uncontrolled, confirming the need for a better management. Allergy did not appear to worsen clinical profile. CI - (c) 2023 Portel et al. FAU - Portel, Laurent AU - Portel L AD - Service de Pneumologie, Centre Hospitalier Robert Boulin, Libourne, France. FAU - Fabry-Vendrand, Caroline AU - Fabry-Vendrand C AD - Astra Zeneca, Courbevoie, France. FAU - Texier, Nathalie AU - Texier N AD - Kappa Sante, Paris, France. FAU - Schwartz, Deborah AU - Schwartz D AD - Kappa Sante, Paris, France. FAU - Capdepon, Audrey AU - Capdepon A AD - Astra Zeneca, Courbevoie, France. FAU - Thabut, Gabriel AU - Thabut G AD - Astra Zeneca, Courbevoie, France. FAU - Debieuvre, Didier AU - Debieuvre D AD - Service de Pneumologie, Hopital Emile Muller, Groupe Hospitalier de la Region Mulhouse Sud-Alsace (GHRMSA), Mulhouse, France. LA - eng PT - Journal Article DEP - 20230104 PL - New Zealand TA - J Asthma Allergy JT - Journal of asthma and allergy JID - 101543450 PMC - PMC9826639 OTO - NOTNLM OT - France OT - asthma OT - eosinophils OT - hospital OT - observational study COIS- CFV, AC and GT are employees of AstraZeneca. NT and DS are employees of Kappa Sante. The authors report no other conflicts of interest in this work. EDAT- 2023/01/12 06:00 MHDA- 2023/01/12 06:01 PMCR- 2023/01/04 CRDT- 2023/01/11 01:50 PHST- 2022/05/19 00:00 [received] PHST- 2022/12/10 00:00 [accepted] PHST- 2023/01/11 01:50 [entrez] PHST- 2023/01/12 06:00 [pubmed] PHST- 2023/01/12 06:01 [medline] PHST- 2023/01/04 00:00 [pmc-release] AID - 375325 [pii] AID - 10.2147/JAA.S375325 [doi] PST - epublish SO - J Asthma Allergy. 2023 Jan 4;16:9-21. doi: 10.2147/JAA.S375325. eCollection 2023.